Sepracor, UMass Sue Over Liquid Clarinex ANDA
The complaint, filed Friday in the U.S. District Court for the District of New Jersey, accuses PAI of infringing U.S. Patent Numbers 7,214,683 and 7,214,684, which cover a pharmaceutical composition and method for liquid Clarinex.
The '683 patent covers the composition for descarboethoxyloratadine, the major metabolite of loratadine. Loratadine is the scientific name for Schering-Plough Corp.'s blockbuster allergy treatment Claritin,...
To view the full article, register now.